CurtisRosebraughMD

Internal Medicine • Ashton, MD

Physician

Join to view full profile

Are you Dr. Rosebraugh?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
17316 Avenleigh Dr
Ashton, MD 20861
Phone+1 301-570-0843

Summary

Dr. Curtis Rosebraugh, MD is a board certified internist in Ashton, Maryland. He is currently licensed to practice medicine in Maryland, District of Columbia, and Texas.

Education & Training

University of Kansas School of MedicineResidency, Internal Medicine, 1986 - 1989
University of Kansas School of MedicineClass of 1986

Certifications & Licensure

KS State Medical License 1989 - 2025
MD State Medical License 1998 - 2025
DC State Medical License 1998 - 2020
TX State Medical License 1994 - 2000
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

200 citations
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Mary H. Parks, Curtis Rosebraugh
The New England Journal of Medicine. 2010-03-17
88 citations
The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
Anthony G. Durmowicz, Robert Lim, Hobart Rogers, Curtis J. Rosebraugh, Badrul A. Chowdhury
Annals of the American Thoracic Society. 2018-01-01
15 citations
Centers for education and research on therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States.
Curtis Rosebraugh, Peter K. Honig, Sally Usdin Yasuda, John C. Pezzullo, Raymond L. Woosley
Clinical Pharmacology and Therapeutics. 2002-01-01

Press Mentions

FDA Approves New Treatment for People with COPDAugust 1st, 2014
FDA Approves New Type 2 Diabetes DrugAugust 1st, 2014
FDA Approves Otezla to Treat Psoriatic ArthritisFebruary 10th, 2016